selected scholarly activity
-
chapters
- Combining Cancer Vaccines with Conventional Therapies. 323-338. 2011
- Adenoviral Vectors for Gene Delivery. 149-182. 2003
- Adenoviral Vectors for Gene Delivery. 166-199. 2003
-
conferences
- 290 IL-15 is required for optimal anti-tumor activity of Vγ9Vδ2 T cells against glioblastoma. Regular and Young Investigator Award Abstracts. a331-a331. 2023
- Abstracts of the Cell Therapy Transplant Canada 2022 Annual Conference. Current Oncology. 9970-10017. 2022
- 261 Evidence for durable anti-tumor responses by TAC-T cells in preclinical models of solid tumors. Journal for ImmunoTherapy of Cancer. A276-A276. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS398-TPS398. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2022
- 101 Engineering gamma/delta T cells with the T-Cell antigen coupler receptor effectively induces antigen-specific tumor cytotoxicity in vitro and in vivo. Journal for ImmunoTherapy of Cancer. A63-A64. 2020
- 94 The T cell antigen coupler (TAC) redirects T cell oncolysis while limiting tonic signaling to create a safer engineered T cell product with a higher threshold for activation. Journal for ImmunoTherapy of Cancer. A59-A60. 2020
- Non-toxic cross-reactivity with healthy tissues supports in vivo expansion and therapeutic efficacy of T cells engineered with synthetic antigen receptors. Cytotherapy. S117-S118. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS761-TPS761. 2020
- Abstract 1424: Preclinical development of TAC01-CD19, a CD19 specific T-cell Antigen Coupler (TAC) therapy for the treatment of CD19-positive B cell malignancies. Cancer Research. 2019
- Development of a CD19-TAC therapy in preparation of human trials. Cytotherapy. S26-S26. 2019
- A Unique Chimeric Antigen Receptor Directed Against ROR-1 Is Effective In-Vitro Against Multiple Tumor Cell Lines Regardless of Cell Of Origin. AKA I Am TAC, Hear Me ROR-1. Laboratory Investigation. 2019
- A Unique Chimeric Antigen Receptor Directed Against ROR-1 Is Effective In-Vitro Against Multiple Tumor Cell Lines Regardless of Cell Of Origin. AKA I Am TAC, Hear Me ROR-1. Modern Pathology. 2019
- T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma. Blood. 962-962. 2018
- Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies. Cancer Research. 1763-1763. 2018
- BCMA-specific TAC receptor-engineered T cells for multiple myeloma. Cytotherapy. S9-S9. 2018
- New neuronal lineage tumor antigen and therapeutic targeting thereof. Cytotherapy. e8-e8. 2018
- Optimizing the culture process of engineered t cells to favor long-term efficacy following adoptive immunotherapy. Cytotherapy. S102-S103. 2018
- T cells engineered with T-cell antigen coupler (TAC) receptors display robust efficacy against solid and liquid tumor xenografts in the absence of any toxicity. Cytotherapy. S8-S8. 2018
- A novel chimeric T cell receptor that operates through the endogenous TCR diverges in biology from conventional CAR T cells. Journal for ImmunoTherapy of Cancer. 2017
- Preclinical evaluation of BCMA-specific TAC receptor-engineered T cells for multiple myeloma. Journal for ImmunoTherapy of Cancer. 2017
- Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma. Cancer Research. 3758-3758. 2017
- Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.. Journal of Clinical Oncology. e14637-e14637. 2017
- Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma. Cancer immunology research. B079-B079. 2016
- THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA. Neuro-Oncology. 98-98. 2016
- Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells. Cancer Research. 1481-1481. 2016
- Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors. Cancer Research. 2300-2300. 2016
- Single-use membrane bioreactor for culturing therapeutic T-cells. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2016
- Engineering antigen specific T regulatory cells for transplant tolerance (P2148). Journal of Immunology. 69.12-69.12. 2013
- Initiation of food allergy by a CD4+ T cell-intrinsic IL-4 program, controlled by OX40L (P6204). Journal of Immunology. 62.1-62.1. 2013
- Utilizing dual-specific CD4+ T cells in combination with oncolytic virotherapy for treatment of cancer (P2118). Journal of Immunology. 132.49-132.49. 2013
- Systems identification approach to reveal the immune fitness landscape in cancer. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2013
- Dual-specific T Cells: Combining Car-engineered T Cells With Oncolytic Virotherapy. Journal of immunotherapy (Hagerstown, Md. : 1997). 728-728. 2012
- Rapamycin Treatment Endows Car-engineered CD8+Effector T Cells With Memory-like Properties Resulting in Enhanced in vivo Engraftment. Journal of immunotherapy (Hagerstown, Md. : 1997). 764-764. 2012
- A novel role for blood endothelial cells in the development and maintenance of immune memory (110.17). Journal of Immunology. 110.17-110.17. 2012
- B16 melanoma inhibits cellular response to Interleukin-12 via multiple mechanisms including paracrine action of Wnt-inducible Signaling Protein-1 (46.10). Journal of Immunology. 46.10-46.10. 2012
- The polyfunctionality of memory CD8+ T cells in response to chronic and acute viral infections is not influenced by age (105.49). Journal of Immunology. 105.49-105.49. 2012
- Discovery, characterization, and development of HLA presented West Nile virus epitopes. Tissue Antigens: immune response genetics. 419-419. 2011
- Tumors adapt rapidly to thwart vaccine-induced T cell attack but this adaptive response can be overcome by manipulation of costimulation and immune checkpoints (48.30). Journal of Immunology. 48.30-48.30. 2011
- Development of a Novel Chimeric Antigen Receptor Targeting the Melanoma Antigen GP75. Journal of immunotherapy (Hagerstown, Md. : 1997). 866-866. 2010
- Investigating the Impact of Autophagy Modulation on Dendritic Cell Cancer Vaccines. Journal of immunotherapy (Hagerstown, Md. : 1997). 892-892. 2010
- 278-P: Phenotype of memory T cells specific for HLA-A*0201 restricted immunodominant West Nile Virus epitopes. Human Immunology. S152-S152. 2009
- Advanced age does not impair the development of functional memory CD8+ T cells following West Nile virus infection (83.4). Journal of Immunology. 83.4-83.4. 2009
- Virus-specific production of IFN-gamma and IL-17 by CD4+ T cells from patients infected with West Nile virus (128.18). Journal of Immunology. 128.18-128.18. 2009
- 191-P: Presentation and immune recognition of West Nile virus epitopes. Human Immunology. S101-S101. 2008
- West Nile Virus Infection: A Model for Human Epitope Immunodominance. The FASEB Journal. 2008
- Cytotoxic therapies can enhance the efficacy of therapeutic cancer Vaccines but the outcome remains limited by antigen selection and the development of antigen-loss variants. Journal of immunotherapy (Hagerstown, Md. : 1997). 868-869. 2007
- 11-OR: Interaction of HLA-a*0201 and west nile virus. Human Immunology. S14-S14. 2007
- F.116. Unravelling the Mechanism of Xenoimmunization By Epitope Mapping. Clinical Immunology. S91-S92. 2006
- The memory CD8 T cell response to influenza virus is limited by costimulation and involves a distinct costimulatory pathway from the primary response. The FASEB Journal. C212-C212. 2003
- Combination therapy with IL-2 and wild-type p53 expressed by Ad-vectors induces tumor regression in vivo without cytokine related toxicity. Cancer Gene Therapy. P137-P137. 1997
-
journal articles
- Reassuring humoral and cellular immune responses to SARS-CoV-2 vaccination in participants with systemic sclerosis.. Immunology Letters. 270:106929. 2024
- CD56 does not contribute to the anti-tumor, tissue homing, and glycolytic capacity of human NK cells.. Journal of Leukocyte Biology. qiae227. 2024
- Electrophilic proximity-inducing synthetic adapters enhance universal T cell function by covalently enforcing immune receptor signaling. Mol Ther Oncol. 32:200842-200842. 2024
- Gluten-Dependent Activation of CD4+ T Cells by MHC Class II–Expressing Epithelium. Gastroenterology. 167:1113-1128. 2024
- Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells. Journal for ImmunoTherapy of Cancer. 12:e006781-e006781. 2024
- Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis. Scientific Reports. 13:22846. 2023
- LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses. Blood. 142:6793-6793. 2023
- Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α. Molecular Oncology. 17:2235-2256. 2023
- Protocol for a longitudinal cohort study of Lyme disease with physical, mental and immunological assessment. BMJ Open. 13:e076833-e076833. 2023
- HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion. Clinical Cancer Research. 29:4289-4305. 2023
- Early humoral and cellular responses after bivalent SARS‐CoV‐2 mRNA‐1273.214 vaccination in long‐term care and retirement home residents in Ontario, Canada: An observational cohort study. Journal of Medical Virology. 95:e29170. 2023
- The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Communications Biology. 6:919. 2023
- Constitutive expression of interleukin-27 diminishes proinflammatory cytokine production without impairing effector function of engineered T cells. Cytotherapy. 25:913-919. 2023
- Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities. EClinicalMedicine. 63:102148-102148. 2023
- Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada. Journal of the American Medical Directors Association. 24:753-758. 2023
- Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada. Journal of the American Medical Directors Association. 24:753-758. 2023
- T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma. Cytotherapy. 25:490-501. 2023
- Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses. Cancer Research. 83:CT202-CT202. 2023
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. 41:TPS750-TPS750. 2023
- LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling. Frontiers in Immunology. 14:1179827. 2023
- Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination. Journal of Immunology. 209:1892-1905. 2022
- Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination.. Journal of Immunology. 209:1892-1905. 2022
- Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. Molecular Metabolism. 61:101498-101498. 2022
- CD28: A roadblock to designing long-lasting CARs?. Journal of Immunology. 208:117.15-117.15. 2022
- The histologic effects of neoadjuvant stereotactic body radiation therapy (SBRT) followed by pulmonary metastasectomy—rationale and protocol design for the Post SBRT Pulmonary Metastasectomy (PSPM) trial. Translational Cancer Research. 11:918-927. 2022
- Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections. Viruses. 13:2239-2239. 2021
- Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. Cytotherapy. 23:820-832. 2021
- Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. iScience. 24:102619-102619. 2021
- Peanut allergen reaction thresholds during controlled food challenges in 2 Canadian randomized studies (Canada-ARM1 and PISCES). Journal of Allergy and Clinical Immunology: In Practice. 9:2524-2526.e2. 2021
- Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency. OncoImmunology. 10:1995168. 2021
- A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy. Cytokine and Growth Factor Reviews. 56:149-159. 2020
- Tonic Signaling Leads to Off-Target Activation of T Cells Engineered with Chimeric Antigen Receptors That Is Not Seen in T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors. Blood. 136:31-32. 2020
- De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Communications Biology. 3:645. 2020
- A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. Molecular Therapy - Oncolytics. 17:278-292. 2020
- The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 26:832-844.e6. 2020
- Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. Journal of Clinical Investigation. 129:5400-5410. 2019
- TGFβ Programs Central Memory Differentiation inEx Vivo–Stimulated Human T Cells. Cancer immunology research. 7:1426-1439. 2019
- Abstract 1424: Preclinical development of TAC01-CD19, a CD19 specific T-cell Antigen Coupler (TAC) therapy for the treatment of CD19-positive B cell malignancies. Cancer Research. 79:1424-1424. 2019
- Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. OncoImmunology. 8:e1512329. 2019
- Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity. Journal of Clinical Investigation. 129:518-530. 2018
- T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies. Blood. 132:3267-3267. 2018
- Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer immunology research. 6:1174-1185. 2018
- The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nature Communications. 9:3049. 2018
- HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. Cell Reports. 24:642-654. 2018
-
AMPK β1 reduces tumor progression and improves survival in p53 null mice. Molecular Oncology. 11:1143-1155. 2017 - Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents. Journal of Infectious Diseases. 216:191-197. 2017
- Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. Cell Death and Disease. 8:e2689-e2689. 2017
- Adaptive Resistance to Cancer Immunotherapy. Advances in Experimental Medicine and Biology. 1036:213-227. 2017
- Tumor-Targeting Domains for Chimeric Antigen Receptor T Cells. Immunotherapy. 9:33-46. 2017
- T‐Cell Phenotypes Predictive of Frailty and Mortality in Elderly Nursing Home Residents. Journal of The American Geriatrics Society. 65:153-159. 2017
- Immunogenicity of Varicella Vaccine and Immunologic Predictors of Response in a Cohort of Elderly Nursing Home Residents. Journal of Infectious Diseases. 214:1905-1910. 2016
- Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans. Journal of Infectious Diseases. 214:1996-2005. 2016
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Journal for ImmunoTherapy of Cancer. 4:1-106. 2016
- IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA. Neuro-Oncology. 18:vi98-vi98. 2016
- Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells. Journal of Immunology. 197:1809-1822. 2016
- Characterization of Proliferating Lesion‐Resident Cells During All Stages of Atherosclerotic Growth. Journal of the American Heart Association. 5:e003945. 2016
- Correction: Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway. PLoS Pathogens. 12:e1005706-e1005706. 2016
- Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. Journal of Immunology. 196:4587-4595. 2016
- Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway. PLoS Pathogens. 12:e1005589-e1005589. 2016
- Bifurcations and Chaotic Dynamics in a Tumour-Immune-Virus System. Mathematical Modelling of Natural Phenomena. 11:65-85. 2016
- Correction: Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS ONE. 11:e0159471-e0159471. 2016
- Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS ONE. 11:e0155947-e0155947. 2016
- Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes. Methods in molecular biology (Clifton, N.J.). 1458:137-157. 2016
- Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. Journal for ImmunoTherapy of Cancer. 3:55. 2015
- T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. Molecular Therapy. 23:1600-1610. 2015
- Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity. Innate immunity. 21:626-634. 2015
- Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncology. 1:359-359. 2015
- Circulating TNF and mitochondrial DNA are major determinants of neutrophil phenotype in the advanced-age, frail elderly. Molecular Immunology. 65:148-156. 2015
- Circulating Muramyl Dipeptide Is Negatively Associated with Interleukin-10 in the Frail Elderly. Inflammation. 38:272-277. 2015
- An Introduction to Automated Flow Cytometry Gating Tools and Their Implementation. Frontiers in Immunology. 6:380. 2015
- Chimeric antigen receptor–engineered T cells as oncolytic virus carriers. Molecular Therapy - Oncolytics. 2:15014-15014. 2015
- Anti-pneumococcal deficits of monocyte-derived macrophages from the advanced-age, frail elderly and related impairments in PI3K-AKT signaling. Human Immunology. 75:1192-1196. 2014
- Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infectious Diseases. 14:246. 2014
- Immunosenescence in the nursing home elderly. BMC Geriatrics. 14:50. 2014
- Analysis of purified Wild type and mutant adenovirus particles by SILAC based quantitative proteomics. Journal of General Virology. 95:2504-2511. 2014
- T helper cell IL-4 drives intestinal Th2 priming to oral peanut antigen, under the control of OX40L and independent of innate-like lymphocytes. Mucosal Immunology. 7:1395-1404. 2014
- Maraba Virus as a Potent Oncolytic Vaccine Vector. Molecular Therapy. 22:420-429. 2014
- Alterations to the Frequency and Function of Peripheral Blood Monocytes and Associations with Chronic Disease in the Advanced-Age, Frail Elderly. PLoS ONE. 9:e104522-e104522. 2014
- Immune Biomarkers Predictive of Respiratory Viral Infection in Elderly Nursing Home Residents. PLoS ONE. 9:e108481-e108481. 2014
- Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor. Molecular Therapy. 22:206-218. 2014
- On-target off-tumor toxicity; when enhancing an NKG2D-based CAR in vitro led to severe toxicities in vivo. Journal for ImmunoTherapy of Cancer. 2:P15-P15. 2014
- Tri-functional T cell receptor antigen coupler (Tri-TAC): a novel method to direct T cells against tumors. Journal for ImmunoTherapy of Cancer. 2:P17-P17. 2014
- A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity. Science Translational Medicine. 5:205ra134. 2013
- Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccines. OncoImmunology. 2:e26013-e26013. 2013
- Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer. Journal of Leukocyte Biology. 93:633-637. 2013
- HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy. Molecular Therapy. 21:887-894. 2013
- Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses. Blood. 121:2432-2439. 2013
- Critical assessment of automated flow cytometry data analysis techniques. Nature Methods. 10:228-238. 2013
- Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. OncoImmunology. 1:419-431. 2012
- IL-15 Can Signal via IL-15Rα, JNK, and NF-κB To Drive RANTES Production by Myeloid Cells. Journal of Immunology. 188:4149-4157. 2012
- Combined mTOR Inhibition and OX40 Agonism Enhances CD8+ T Cell Memory and Protective Immunity Produced by Recombinant Adenovirus Vaccines. Molecular Therapy. 20:860-869. 2012
- Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines.. Molecular Therapy. 20:860-869. 2012
- A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model. Integrative Biology (United Kingdom). 4:925-925. 2012
- The Polyfunctionality of Human Memory CD8+ T Cells Elicited by Acute and Chronic Virus Infections Is Not Influenced by Age. PLoS Pathogens. 8:e1003076-e1003076. 2012
- Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9:214. 2011
- Multi-Stability and Multi-Instability Phenomena in a Mathematical Model of Tumor-Immune-Virus Interactions. Bulletin of Mathematical Biology. 73:2932-2961. 2011
- Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model. Gene Therapy. 18:986-995. 2011
- Genetic Variants and Susceptibility to Neurological Complications Following West Nile Virus Infection. Journal of Infectious Diseases. 204:1031-1037. 2011
- Novel method for differentiation between Trastuzumab and host adaptive response. Molecular Immunology. 48:1882-1885. 2011
- Optimizing vaccine-induced CD8+T-cell immunity: focus on recombinant adenovirus vectors. Expert Review of Vaccines. 10:1307-1319. 2011
- IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells. Cancer Research. 71:2497-2506. 2011
- Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production. Cancer Immunology, Immunotherapy. 60:381-388. 2011
- CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. Blood. 117:1146-1155. 2011
- Association between HLA Class I and Class II Alleles and the Outcome of West Nile Virus Infection: An Exploratory Study. PLoS ONE. 6:e22948-e22948. 2011
- IL-1α/IL-1R1 Expression in Chronic Obstructive Pulmonary Disease and Mechanistic Relevance to Smoke-Induced Neutrophilia in Mice. PLoS ONE. 6:e28457-e28457. 2011
- Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models. Bulletin of Mathematical Biology. 73:2-32. 2011
- Surface Phenotype and Functionality of WNV Specific T Cells Differ with Age and Disease Severity. PLoS ONE. 5:e15343-e15343. 2010
- Mesenchymal Stromal Cells Expressing ErbB-2/neu Elicit Protective Antibreast Tumor Immunity In vivo, Which Is Paradoxically Suppressed by IFN-γ and Tumor Necrosis Factor-α Priming. Cancer Research. 70:7742-7747. 2010
- Identification of CD8+ T Cell Epitopes in the West Nile Virus Polyprotein by Reverse-Immunology Using NetCTL. PLoS ONE. 5:e12697-e12697. 2010
- Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanoma. Journal of Theoretical Biology. 265:467-480. 2010
- Potentiating Cancer Immunotherapy Using an Oncolytic Virus. Molecular Therapy. 18:1430-1439. 2010
- Processing of Tumor Antigen Differentially Impacts the Development of Helper and Effector CD4+ T-cell Responses. Molecular Therapy. 18:1224-1232. 2010
- Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen. Journal of Immunology. 184:4269-4275. 2010
- Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes – relevance for vaccine design. Immunome Research. 6:S6-S6. 2010
- Persistence of Transgene Expression Influences CD8+T-Cell Expansion and Maintenance following Immunization with Recombinant Adenovirus. Journal of Virology. 83:12027-12036. 2009
- Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus. Molecular Therapy. 17:1814-1821. 2009
- Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood. 114:2632-2638. 2009
- Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity. Molecular Therapy. 17:1465-1472. 2009
- CD4+ T‐cell‐mediated anti‐tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis. European Journal of Immunology. 39:1252-1259. 2009
- Neoadjuvant Vaccination Provides Superior Protection against Tumor Relapse following Surgery Compared with Adjuvant Vaccination. Cancer Research. 69:3979-3985. 2009
- High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome. Cancer Gene Therapy. 16:338-350. 2009
- Characterizing Complex Polysera Produced by Antigen-Specific Immunization through the Use of Affinity-Selected Mimotopes. PLoS ONE. 4:e5309-e5309. 2009
- Deciphering epitope specificities within polyserum using affinity selection of random peptides and a novel algorithm based on pattern recognition theory. Molecular Immunology. 46:429-436. 2009
- A novel computer algorithm improves antibody epitope prediction using affinity-selected mimotopes: A case study using monoclonal antibodies against the West Nile virus E protein. Molecular Immunology. 46:125-134. 2008
- The Memory T Cell Response to West Nile Virus in Symptomatic Humans following Natural Infection Is Not Influenced by Age and Is Dominated by a Restricted Set of CD8+ T Cell Epitopes. Journal of Immunology. 181:1563-1572. 2008
- Tumor Protection Following Vaccination With Low Doses of Lentivirally Transduced DCs Expressing the Self-antigen erbB2. Molecular Therapy. 16:607-617. 2008
- Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes. Proceedings of the National Academy of Sciences of the United States of America. 105:2981-2986. 2008
- Enhanced Antitumor Immunity Elicited by Dendritic Cell Vaccines Is a Result of Their Ability to Engage Both CTL and IFNγ-producing NK Cells. Molecular Therapy. 16:411-418. 2008
- Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.. Molecular Therapy. 16:411-418. 2008
- Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene. 27:208-217. 2008
- Induction of Epitope-Specific Neutralizing Antibodies against West Nile Virus. Journal of Virology. 81:11828-11839. 2007
- The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector. Cellular Immunology. 250:55-67. 2007
- Antigen Presentation by Exosomes Released from Peptide-Pulsed Dendritic Cells Is not Suppressed by the Presence of Active CTL. Journal of Immunology. 179:5024-5032. 2007
- Critical Negative Regulation of Type 1 T Cell Immunity and Immunopathology by Signaling Adaptor DAP12 during Intracellular Infection. Journal of Immunology. 179:4015-4026. 2007
- Critical negative regulation of immunopathology by signaling intracellular infection. Journal of Immunology. 179:4015-4026. 2007
- Elevated Frequencies of Self-reactive CD8+ T Cells following Immunization with a Xenoantigen Are Due to the Presence of a Heteroclitic CD4+ T-Cell Helper Epitope. Cancer Research. 67:6459-6467. 2007
- T-cell immunity generated by recombinant adenovirus vaccines. Expert Review of Vaccines. 6:347-356. 2007
- On the Role of CD4+ T Cells in the CD8+ T-Cell Response Elicited by Recombinant Adenovirus Vaccines. Molecular Therapy. 15:997-1006. 2007
- On the role of CD4(+) T cells in the CD8(+) T-cell response elicited by recombinant adenovirus vaccines. Molecular Therapy. 15:997-1006. 2007
- Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine. 25:1342-1352. 2007
- Development of Cell-Based Tuberculosis Vaccines: Genetically Modified Dendritic Cell Vaccine Is a Much More Potent Activator of CD4 and CD8 T Cells Than Peptide- or Protein-Loaded Counterparts. Molecular Therapy. 13:766-775. 2006
- Inhalation Tolerance Is Induced Selectively in Thoracic Lymph Nodes but Executed Pervasively at Distant Mucosal and Nonmucosal Tissues. Journal of Immunology. 176:2568-2580. 2006
- Recombinant Adenovirus Vaccines Can Successfully Elicit CD8+ T Cell Immunity under Conditions of Extreme Leukopenia. Molecular Therapy. 13:270-279. 2006
- The CD8+ T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity. Journal of Immunology. 176:200-210. 2006
- Recent Advances in the Development of Adenovirus- and Poxvirus- Vectored Tuberculosis Vaccines. Current Gene Therapy. 5:485-492. 2005
- Semliki Forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity. Vaccine. 23:4189-4194. 2005
- Cutaneous Antigen Priming via Gene Gun Leads to Skin-Selective Th2 Immune-Inflammatory Responses. Journal of Immunology. 174:1664-1674. 2005
- The efficacy of electroporated plasmid vaccines correlates with long-term antigen production in vivo. Vaccine. 22:2517-2523. 2004
- CTL-Dependent and -Independent Antitumor Immunity Is Determined by the Tumor Not the Vaccine. Journal of Immunology. 172:5200-5205. 2004
- Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin. Cancer Research. 64:1509-1514. 2004
- Helper-Dependent Adenoviral Vectors Containing Modified Fiber for Improved Transduction of Developing and Mature Muscle Cells. Human Gene Therapy. 15:179-188. 2004
- TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. Journal of Clinical Investigation. 113:401-413. 2004
- TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. Journal of Clinical Investigation. 113:401-413. 2004
- A Switch in Costimulation from CD28 to 4-1BB during Primary versus Secondary CD8 T Cell Response to Influenza In Vivo. Journal of Immunology. 172:981-988. 2004
- Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein. Blood. 103:93-99. 2004
- DetailedAnalysis of the CD8 + T-Cell Response followingAdenovirusVaccination. Journal of Virology. 77:13407-13411. 2003
- Electroporation Enables Plasmid Vaccines to Elicit CD8+ T Cell Responses in the Absence of CD4+ T Cells. Journal of Immunology. 171:3379-3384. 2003
- Super-activated interferon-regulatory factors can enhance plasmid immunization. Vaccine. 21:1363-1370. 2003
- Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Therapy. 10:251-260. 2003
- In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors.. Cancer Research. 62:5148-5152. 2002
- The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opinion on Biological Therapy. 2:75-85. 2002
- Dendritic Cell-Derived IL-12 Is Not Required for the Generation of Cytotoxic, IFN-γ-Secreting, CD8+ CTL In Vivo. Journal of Immunology. 167:5027-5033. 2001
- Role of Dendritic Cell-Derived Cytokines in Immune Regulation. Current Pharmaceutical Design. 7:977-992. 2001
- Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.. Cancer Research. 60:3247-3253. 2000
- Intravenous Administration of Stabilized Antisense Lipid Particles (SALP) Leads to Activation and Expansion of Liver Natural Killer Cells. Nucleic Acid Therapeutics. 10:217-224. 2000
- Activation of host antitumoral responses by cationic lipid/DNA complexes. Cancer Gene Therapy. 7:353-359. 2000
- Effects of Stuffer DNA on Transgene Expression from Helper-Dependent Adenovirus Vectors. Journal of Virology. 73:8027-8034. 1999
- Adenoviral vectors: prospects for gene delivery to the central nervous system. Gene Therapy. 6:1349-1350. 1999
- Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy. 5:1400-1409. 1998
- Combination Therapy with Interleukin-2 and Wild-Type p53 Expressed by Adenoviral Vectors Potentiates Tumor Regression in a Murine Model of Breast Cancer. Human Gene Therapy. 9:707-718. 1998
- A Double Recombinant Adenovirus Expressing the Costimulatory Molecule B7-1 (Murine) and Human IL-2 Induces Complete Tumor Regression in a Murine Breast Adenocarcinoma Model. Journal of Immunology. 160:2531-2538. 1998
- ANTI-INTERLEUKIN-12 THERAPY PROTECTS MICE IN LETHAL ENDOTOXEMIA BUT IMPAIRS BACTERIAL CLEARANCE IN MURINE ESCHERICHIA COLI PERITONEAL SEPSIS. Shock. 8:349-356. 1997
- Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Therapy. 4:1069-1076. 1997
- Dendritic Cells Transduced with an Adenoviral Vector Encoding a Model Tumor-Associated Antigen for Tumor Vaccination. Human Gene Therapy. 8:1355-1363. 1997
- Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12. Human Gene Therapy. 7:1995-2002. 1996
- IL-12 gene therapy protects mice in lethal Klebsiella pneumonia.. Journal of Immunology. 157:3006-3012. 1996
- Construction of a Double Recombinant Adenovirus Vector Expressing a Heterodimeric Cytokine:In VitroandIn VivoProduction of Biologically Active Interleukin-12. Human Gene Therapy. 7:333-342. 1996
- Effect of alkyl-N-purine DNA glycosylase overexpression on cellular resistance to bifunctional alkylating agents. Biochemical Pharmacology. 50:39-44. 1995
- Potentiation of chlorambucil toxicity in B-CLL lymphocytes using the DNA synthesis inhibitors aphidicolin and 1-β-d-arabinofuranosylcytosine. Biochemical Pharmacology. 50:131-135. 1995
- Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS. 336:269-278. 1995
- DNA repair enzyme expression in chronic lymphocytic leukemia vis-à-vis nitrogen mustard drug resistance. Cancer Letters. 90:139-148. 1995
- The use of adenoviral vectors for gene therapy and gene transfer in vivo. Current Opinion in Biotechnology. 6:590-595. 1995
- Poly(ADP-ribose) polymerase can bind melphalan damaged DNA.. Cancer Research. 53:5370-5373. 1993
- Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents.. Cancer Research. 53:3237-3240. 1993
- Lack of evidence for a high-affinity sarcosinamide carrier or a catecholamine carrier in Calu-1 lung-cancer cells, HT-29 colon-cancer cells, and DHF fibroblasts. Cancer Chemotherapy and Pharmacology. 31:146-150. 1992
- Increased DNA Synthesis and Repair-Enzyme Expression in Lymphocytes From Patients With Chronic Lymphocytic Leukemia Resistant to Nitrogen Mustards. Journal of the National Cancer Institute. 83:557-564. 1991
-
preprints
- Endogenous CD28 drives CAR T cell responses in multiple myeloma 2024
- Protection from Omicron infection in residents of nursing and retirement homes in Ontario, Canada 2022
- CMV seropositivity in older adults changes the T cell repertoire, but does not prevent antibody or cellular responses to SARS-CoV-2 vaccination 2022
- Lasting changes to circulating leukocytes in people with mild SARS-CoV-2 infections 2021